Grufity logoGrufity logo
StocksFundsSearch Filings

Boston Scientific Corp Stock Research

BSX

51.06USD-0.48(-0.93%)Market Closed

Market Summary

USD51.06-0.48
Market Closed
-0.93%

BSX Alerts

BSX Stock Price

BSX RSI Chart

BSX Valuation

Market Cap

74.1B

Price/Earnings (Trailing)

106.12

Price/Sales (Trailing)

5.84

EV/EBITDA

29.87

Price/Free Cashflow

78.97

BSX Price/Sales (Trailing)

BSX Profitability

EBT Margin

9.00%

Return on Equity

3.97%

Return on Assets

2.15%

Free Cashflow Yield

1.27%

BSX Fundamentals

BSX Revenue

Revenue (TTM)

13.0B

Revenue Y/Y

12%

Revenue Q/Q

4.53%

BSX Earnings

Earnings (TTM)

698.0M

Earnings Y/Y

47.37%

Earnings Q/Q

-25.53%

Price Action

52 Week Range

34.9854.17
(Low)(High)

Last 7 days

-4.8%

Last 30 days

-0.1%

Last 90 days

8.6%

Trailing 12 Months

27.2%

BSX Financial Health

Current Ratio

1.51

Debt/Equity

0.51

Debt/Cashflow

0.17

BSX Investor Care

Shares Dilution (1Y)

0.55%

Diluted EPS (TTM)

0.59

Peers (Alternatives to Boston Scientific)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
110.8B
19.0B
-8.78% 16.43%
46.98
6.01
8.73% 30.37%
107.5B
6.4B
4.05% 37.44%
81.96
16.72
8.89% -20.19%
74.1B
13.0B
-0.08% 27.20%
106.12
5.84
7.26% -32.95%
71.3B
18.8B
-6.73% -3.13%
44.09
3.79
-1.96% -15.83%
49.7B
5.5B
-6.18% -16.80%
33.38
9.03
2.68% -3.23%
MID-CAP
7.2T
557.2M
-1.64% 66.40%
82.2K
16.8K
86.42% 730.06%
11.7B
884.6M
7.85% 115.97%
1.8K
13.2
13.08% 200.12%
5.9B
1.1B
-8.20% -19.98%
34.14
5.75
11.20% 53.04%
3.6B
430.0M
-11.89% -12.63%
-34.73
8.45
26.13% 15.73%
1.7B
794.7M
-29.15% -60.56%
-8.43
2.16
7.73% -3556.34%
SMALL-CAP
1.6B
389.0M
-3.76% 82.19%
-10.63
4.18
44.08% 6.96%
1.2B
150.7M
-30.80% 0.49%
-21.65
7.87
40.31% 1.80%
1.1B
814.3M
-20.14% -16.22%
24.47
1.34
6.96% 121.89%
839.3M
239.8M
0.70% 0.15%
-22.16
3.5
-4.74% -31.15%

Financials for Boston Scientific

Income Statement (Last 12 Months)
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Revenue2.9%13,04512,68212,56712,32912,162
Gross Profit3.2%9,0058,7278,6508,4918,390
Operating Expenses2.7%7,2707,0787,2237,0357,095
  S&GA Expenses3.4%4,6754,5204,5104,4444,400
EBITDA10.3%2,7472,4902,7392,544-
EBITDA Margin9.3%0.22*0.20*0.22*0.21*-
Earnings Before Taxes25.3%1,4301,1418651,103907
EBT Margin30.7%0.09*0.07*0.09*0.07*-
Interest Expenses-45.5%256470493516538
Net Income6.9%698653884810-
Net Income Margin5.9%0.06*0.05*0.07*0.07*-
Free Cahsflow69.0%938555593928-
Balance Sheet
(In Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Assets1.3%32,89232,46931,94732,18932,337
  Current Assets-1.0%5,7045,7605,1445,0835,065
    Cash Equivalents-17.8%763928338276325
  Inventory9.8%2,0501,8671,7881,7521,736
  Net PPE1.3%2,4782,4462,2732,2462,265
  Goodwill2.7%13,26912,92012,85212,88312,949
  Current Liabilities7.4%4,0833,8033,5493,8834,275
  Long Term Debt-4.7%8,4958,9158,5648,8029,067
Shareholder's Equity3.1%18,10917,57317,64017,25116,735
  Retained Earnings40.0%-450-750-876-1,050-1,296
  Additional Paid-In Capital0.3%20,35620,28920,21920,10320,043
Shares Outstanding0.1%1,4321,4301,428--
Cashflow (Last 12 Months)
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Cashflow From Operations16.3%1,7741,5261,1971,1921,528
  Share Based Compensation1.4%223220214207199
Cashflow From Investing54.2%-921-2,011-2,289-3,271-3,242
Cashflow From Financing-11.5%-611-548-557-352-6.00
  Dividend Payments0%55.0055.0055.0055.0055.00
  Buy Backs-0.00----

Risks for BSX

What is the probability of a big loss on BSX?

35.4%


Probability that Boston Scientific stock will be more than 20% underwater in next one year

18.5%


Probability that Boston Scientific stock will be more than 30% underwater in next one year.

16.1%


Probability that Boston Scientific stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does BSX drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Boston Scientific was unfortunately bought at previous high price.

Drawdowns

Returns for BSX

Cumulative Returns on BSX

18.7%


10-Year Cumulative Returns

12.4%


7-Year Cumulative Returns

11.0%


5-Year Cumulative Returns

12.2%


3-Year Cumulative Returns

What are the long-term rolling returns for BSX?

FIve years rolling returns for Boston Scientific.

Annualized Returns

Which funds bought or sold BSX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-05-23
Toroso Investments, LLC
added
114
3,805,000
6,688,000
0.11%
2023-05-23
Front Row Advisors LLC
unchanged
-
1,000
15,000
0.01%
2023-05-23
Brookfield Corp /ON/
reduced
-48.11
-8,412,860
10,754,900
0.04%
2023-05-22
Raleigh Capital Management Inc.
new
-
135,281
135,281
0.07%
2023-05-22
Westover Capital Advisors, LLC
reduced
-7.01
4,739
863,418
0.32%
2023-05-22
PUTNAM INVESTMENTS LLC
reduced
-1.54
338,753
10,484,800
0.02%
2023-05-22
FDx Advisors, Inc.
unchanged
-
-
415,000
0.02%
2023-05-22
PUTNAM INVESTMENTS LLC
reduced
-33.83
-94,343,800
237,236,000
0.38%
2023-05-22
AMERIPRISE FINANCIAL INC
reduced
-12.44
-4,900,380
55,631,600
0.02%
2023-05-22
AMERIPRISE FINANCIAL INC
reduced
-0.85
32,526,500
483,597,000
0.16%

1–10 of 43

Latest Funds Activity

Are funds buying BSX calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own BSX
No. of Funds

Boston Scientific News

Nasdaq
Guru Fundamental Report for BSX.
Nasdaq,
9 hours ago
U.S News & World Report Money
9 of the Best Mutual Funds to Buy Now.
U.S News & World Report Money,
33 hours ago
StockNews.com
Zacks Investment Research

Schedule 13G FIlings of Boston Scientific

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2023
blackrock inc.
9.6%
137,802,646
SC 13G/A
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Feb 09, 2023
vanguard group inc
8.29%
118,773,794
SC 13G/A
Feb 08, 2023
massachusetts financial services co /ma/
5.8%
82,467,469
SC 13G/A
Feb 06, 2023
wellington management group llp
4.03%
57,736,340
SC 13G/A
Jan 24, 2023
blackrock inc.
9.8%
140,116,265
SC 13G/A
Feb 09, 2022
vanguard group inc
7.83%
111,621,630
SC 13G/A
Feb 09, 2022
fmr llc
-
0
SC 13G
Feb 08, 2022
blackrock inc.
9.0%
127,917,655
SC 13G/A
Feb 04, 2022
wellington management group llp
5.22%
74,421,509
SC 13G/A

BSX Fair Value

Recent SEC filings of Boston Scientific

View All Filings
Date Filed Form Type Document
May 25, 2023
SD
SD
May 23, 2023
144
Notice of Insider Sale Intent
May 17, 2023
4
Insider Trading
May 17, 2023
4
Insider Trading
May 16, 2023
144
Notice of Insider Sale Intent
May 15, 2023
144
Notice of Insider Sale Intent
May 09, 2023
8-K
Current Report
May 05, 2023
4
Insider Trading
May 05, 2023
4
Insider Trading
May 05, 2023
4
Insider Trading

Latest Insider Trading transactions for BSX

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-05-16
Fitzgerald Joseph Michael
sold
-3,394,860
53.5982
-63,339
evp & group pres, cardiology
2023-05-16
Fitzgerald Joseph Michael
acquired
744,527
13.08
56,921
evp & group pres, cardiology
2023-05-15
Carruthers Wendy
sold
-624,333
53.4944
-11,671
evp, human resources
2023-05-15
Carruthers Wendy
acquired
94,953
14.818
6,408
evp, human resources
2023-05-04
Sununu John E
acquired
-
-
3,946
-
2023-05-04
Zane Ellen M
acquired
-
-
3,946
-
2023-05-04
Connors Nelda J
acquired
-
-
3,946
-
2023-05-04
WICHMANN DAVID S
acquired
-
-
3,946
-
2023-05-04
Dockendorff Charles J
acquired
-
-
3,946
-
2023-05-04
ROUX DAVID J
acquired
-
-
3,946
-

1–10 of 50

Michael F. Mahoney
41000
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

BSX Income Statement

2023-03-31
Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Millions, $ in Millions
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Net sales$ 3,389$ 3,026
Cost of products sold1,040955
Gross profit2,3492,071
Operating expenses:  
Selling, general and administrative expenses1,2151,060
Research and development expenses337319
Royalty expense1112
Amortization expense203198
Contingent consideration net expense (benefit)1212
Restructuring net charges (credits)204
Operating expenses1,7971,605
Operating income (loss)552466
Other income (expense):  
Interest expense(65)(279)
Other, net(43)(31)
Income (loss) before income taxes444156
Income tax expense (benefit)13145
Net income (loss)314110
Preferred stock dividends(14)(14)
Net income (loss) attributable to noncontrolling interests00
Net income (loss) attributable to Boston Scientific common stockholders$ 300$ 97
Net income (loss) per common share — basic$ 0.21$ 0.07
Net income (loss) per common share — diluted$ 0.21$ 0.07
Weighted-average shares outstanding  
Basic1,435.81,427.8
Diluted1,446.01,438.4

BSX Balance Sheet

2023-03-31
Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Millions
Mar. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 570$ 928
Trade accounts receivable, net2,0761,970
Inventories2,0501,867
Prepaid income taxes296264
Other current assets711731
Total current assets5,7045,760
Property, plant and equipment, net2,4782,446
Goodwill13,26912,920
Other intangible assets, net6,0605,902
Deferred tax assets3,9003,942
Other long-term assets1,4821,500
TOTAL ASSETS32,89232,469
Current liabilities:  
Current debt obligations51020
Accounts payable868862
Accrued expenses1,9182,160
Other current liabilities787761
Total current liabilities4,0833,803
Long-term debt8,4958,915
Deferred income taxes210144
Other long-term liabilities1,9952,035
Commitments and contingencies
Stockholders’ equity  
Preferred stock, $0.01 par value - authorized 50,000,000 shares - issued 10,062,500 shares as of March 31, 2023 and December 31, 202200
Common stock, $0.01 par value - authorized 2,000,000,000 shares - issued 1,700,828,873 shares as of March 31, 2023 and 1,696,633,993 shares as of December 31, 20221717
Treasury stock, at cost - 263,289,848 shares as of March 31, 2023 and December 31, 2022(2,251)(2,251)
Additional paid-in capital20,35620,289
Accumulated deficit(450)(750)
Accumulated other comprehensive income (loss), net of tax178269
Total stockholders’ equity17,85017,573
Noncontrolling interests2590
Total equity18,10917,573
TOTAL LIABILITIES AND EQUITY$ 32,892$ 32,469